Transdiagnostic Metacognitive Therapy Compared to Disorder-Specific Cognitive-Behavioral T
Background Anxiety disorders are the most prevalent psychiatric disorders around the world. Effective treatment consists of pharmacotherapy or psychological treatment based on cognitive-behavioral therapy (CBT) and these treatment options are recommended in clinical guidelines, with CBT as the first-line treatment for
| Condition(s) | Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Posttraumatic Stress Disorder (PTSD) |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Background Anxiety disorders are the most prevalent psychiatric disorders around the world. Effective treatment consists of pharmacotherapy or psychological treatment based on cognitive-behavioral therapy (CBT) and these treatment options are recommended in clinical guidelines, with CBT as the first-line treatment for anxiety disorders. However, only 50% of patients with anxiety disorders achieve remission status following CBT and 20% of patients drop out of CBT. Metacognitive therapy (MCT) represents an alternative treatment approach to CBT. The theoretical model of MCT emphasizes the role of dysfunctional metacognitions (rather than cognitions, as in CBT), particularly negative metacognitions, in the development and maintenance of anxiety disorders and other psychiatric disorders. Metaco |
| Who can participate | Inclusion Criteria: * 18 years of age or older * A principal (most interfering and/or severe) diagnosis of GAD, SAD or PTSD * If on pharmacological treatment, no change in dose during the last six weeks * Ability to read and speak Swedish Exclusion Criteria: * A current diagnosis of psychotic disorder, bipolar disorder, neurocognitive disorder, or moderate to severe substance use disorder * Acute risk of suicide * Simultaneous psychological treatment |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Karolinska Institutet |
| Locations | Stockholm, Sweden |
| Start date | 2025-08-27 |
| NCT ID | NCT06937892 |
| Official listing | https://clinicaltrials.gov/study/NCT06937892 |